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Background
Systematic reviews (SRs) using individual participant
data (IPD) are often referred to as the gold standard due
to improved precision and reliability. Furthermore, they
may identify treatment by participant subgroup interac-
tions, enabling better targeting of treatments. IPD SRs
have enormous potential to influence clinical guidelines,
however their uptake by guideline developers, as Level 1
evidence, is unclear.
Objectives
We aimed to assess the impact of IPD SRs of interventions
on clinical guidelines across a variety of healthcare areas.
Methods
30 eligible IPD SRs published from 2008 to 2010 spanning
clinical areas including cancer, cardiovascular disease, and
epilepsy were identified from records of the Cochrane IPD
Meta-analysis Methods Group. Clinical guidelines across
corresponding healthcare areas, published or revised since
2010, were searched for references to these IPD SRs.
Details of recommendations based on the results of these
reviews and citations of other relevant SRs were collected.
Results
Searches identified 227 potentially relevant clinical guide-
lines. Preliminary results are based on four IPD SRs in
cancer and 34 relevant guidelines. Each of the four IPD
SRs was cited in 2 to 5 guidelines, however citations were
only identified in 11/34 guidelines (32%). Three of the 14
guidelines also cited aggregate data SRs, with little distinc-
tion between results of IPD or aggregate data SRs.
Further results for all 30 IPD SRs and 227 guidelines
will be presented.
Conclusions
Results of this study will help develop guidance regarding
how best to use IPD SRs to inform guidelines and thus
impact on clinical practice.
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